AntagomiR-19a Induced Better Responsiveness to Bortezomib in Myeloma Cell Lines
Objective: Multiple myeloma (MM) is the clonal proliferation of neoplastic plasma cells in the bone marrow. Although bortezomib (BTZ) is a crucial drug for the treatment of MM, drug resistance is a major problem. OncomiR-19a plays an oncogenic role in many cancers, including MM; however, the functio...
Enregistré dans:
| Auteurs principaux: | , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Royan Institute (ACECR), Tehran
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/d0a174c47a674058bb15b47c9426b3fd |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|